Drug Patent Applications: How to Draft Claims That Hold Up in Court and Block Generic Entry
Section 1: The Patent as a Balance Sheet Asset A pharmaceutical patent is not a legal formality. It is the […]
Decoding Drug Pricing Models: A Strategic Guide to Market Domination
Introduction: The End of the Free Pricing Era The pharmaceutical industry has long operated under a unique social contract: invest
Decoding Drug Pricing Models: A Strategic Guide to Market Domination Read Post »
Biosimilar Extrapolation of Indications: The Complete Regulatory, IP, and Investment Playbook
1. Why Extrapolation Is the Most Valuable Two Words in Biosimilar Development Biologics occupy a peculiar place in the pharmaceutical
A Definitive Guide to Valuing Pharmaceutical and Biotech Companies
1. Introduction: The Economic Imperative of Valuation in Life Sciences The valuation of pharmaceutical and biotechnology entities constitutes one of
A Definitive Guide to Valuing Pharmaceutical and Biotech Companies Read Post »
CDMO Pricing: The Total Cost of Ownership Playbook for Pharma IP Teams and Portfolio Managers
The New Economic Reality of Drug Manufacturing The days of selecting a Contract Development and Manufacturing Organization on the lowest
M&A in Generic Drug Development: IP Valuation, Patent Strategy, and Dealmaking Intelligence
Introduction: The Market Paradox That Drives Every Deal The global generic drug industry has spent the last decade locked in
Biopharma Intelligence Infrastructure: The Definitive Technical Guide to Raw Data Platforms, AI Architecture, and Competitive Signal Processing
1. What Biopharma Intelligence Actually Does (and What Most Firms Think It Does) 1.1 The Operational Definition Biopharmaceutical business intelligence
Europe’s €30B Biologics Patent Cliff: The Complete Biosimilar Strategy Guide for Generic Manufacturers, IP Teams, and Investors
1. Executive Summary Between now and 2032, an estimated 110 biological medicines in Europe will lose intellectual property protection, with
Post-ANDA Patent Strategy: The Complete Playbook for Generic Market Domination
Generic drug development past the ANDA filing date is where most companies either build durable competitive moats or bleed out
Post-ANDA Patent Strategy: The Complete Playbook for Generic Market Domination Read Post »
